H

Helixmith Co Ltd
KOSDAQ:084990

Watchlist Manager
Helixmith Co Ltd
KOSDAQ:084990
Watchlist
Price: 5 910 KRW -1.99% Market Closed
Market Cap: ₩272.4B

Net Margin

-140.9%
Current
Improving
by 835.5%
vs 3-y average of -976.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-140.9%
=
Net Income
₩-5.3B
/
Revenue
₩3.7B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-140.9%
=
Net Income
₩-5.3B
/
Revenue
₩3.7B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Helixmith Co Ltd
KOSDAQ:084990
277.7B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in Korea
Percentile
5th
Based on 2 632 companies
5th percentile
-140.9%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Helixmith Co Ltd
Glance View

Market Cap
272.4B KRW
Industry
Biotechnology

Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.

Helixmith Co Ltd Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-140.9%
=
Net Income
₩-5.3B
/
Revenue
₩3.7B
What is Helixmith Co Ltd's current Net Margin?

The current Net Margin for Helixmith Co Ltd is -140.9%, which is above its 3-year median of -976.5%.

How has Net Margin changed over time?

Over the last 3 years, Helixmith Co Ltd’s Net Margin has increased from -1 836.1% to -140.9%. During this period, it reached a low of -1 836.1% on Aug 30, 2022 and a high of -140.9% on Oct 30, 2025.

Back to Top